Skip to main content

Carey John F's Form 4 filing

TransMedics Group, Inc. (TMDX) · filed Oct 4, 2022

Accession no.
0000899243-22-032663
Filed
Oct 4, 2022, 4:31 PM ET
Trade date
Oct 3, 2022
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $126.3K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Carey John FCIK 0001774272Officer (VP of Operations)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 3, 2022Common StockMOption exerciseAcquired+784$2.21+$1,732.641,555Direct
Oct 3, 2022Common StockMOption exerciseAcquired+2,216$0.28+$620.483,771Direct
Oct 3, 2022Common StockSSaleDisposed−2,320$41.93F2−$97,277.61,451Direct
Oct 3, 2022Common StockSSaleDisposed−680$42.63F3−$28,988.4771Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Oct 3, 2022Common StockMOption exerciseDisposed−784$0.00$02,000Direct
Oct 3, 2022Common StockMOption exerciseDisposed−2,216$0.00$012,273Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $41.51 to $42.50, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Referenced by the price of 1 transaction in Table I.

F3

The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $42.52 to $42.95, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)